d6-[18f]fluoropropyl-(+)-dihydrotetrabenazine

**d6-[18F]fluoropropyl-(+)-dihydrotetrabenazine** is a deuterated, fluorine-18 labeled radiopharmaceutical used as a PET imaging agent to quantify vesicular monoamine transporter 2 (**VMAT2**) binding sites in the brain. The compound is a deuterated analog of [18F]FP-(+)-DTBZ, which itself is derived from dihydrotetrabenazine (DTBZ). Deuterium substitution enhances metabolic stability, reduces in vivo defluorination, and improves PET signal quality and quantification. **d6-[18F]FP-(+)-DTBZ** is primarily developed for imaging and diagnosing Parkinson’s disease and other neurodegenerative diseases, as it highlights monoaminergic neuron density and activity in vivo by specific binding to VMAT2, which is highly expressed in dopaminergic neurons and pancreatic beta-cells. Human studies show improved safety, biodistribution, and brain region signal compared to non-deuterated tracers, making it a valuable tool to assess neurodegeneration and disease progression[1][5].

Other names

d6-[18f]fp-(+)-dtbz[18f]f-d6-fp-dtbz18f-d6-av-13318f-p17-059